Junshi Biosciences and Coherus plan to evaluate the toripalimab + JS006 combination in clinical trials in multiple tumor types Combinations of PD-1 + TIGIT inhibitors have potential to expand checkpoint inhibitor utilization to new tumors and lines of therapy SHANGHAI,

Successful performance of plasma compression prototype confirms path to commercialization General Fusion’s plasma compression prototype VANCOUVER, British Columbia, Jan. 10, 2022 (GLOBE NEWSWIRE) — General Fusion announced today it has successfully achieved several aggressive performance goals of a prototype system

BEIJING and LONDON and PARIS and SAN FRANCISCO, Jan. 10, 2022 (GLOBE NEWSWIRE) — After overwhelming demand, creative offers and global inquires from it’s recent September 2021 billion dollar auction, A4BET® is announcing a time sensitive bidding process to acquire

CHIPPENHAM, United Kingdom, Jan. 10, 2022 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq: DSGX) (TSX: DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that UK-based sports and hobbies retailer Fishing Tackle & Bait has successfully transformed its

Khondrion completes enrolment in KHENERGYZE Phase IIb trial evaluating sonlicromanol in adult patients with MELAS spectrum disorders NIJMEGEN, the Netherlands – 10 January 2022: Khondrion, a clinical stage biopharmaceutical company discovering and developing therapies targeting primary mitochondrial diseases, today announced